Companies /Healthcare

Oscar Health Inc - Class A

NYSE: OSCR Healthcare Plans
$32.04
▲ $0.06 (+0.19%) today
Markets open · 10:11am ET

Q1 2026 Earnings

Reported May 6, 2026, 6:19am ET · SEC source
$2.07
Beat +88.18%
EPS · est. $1.10
$4.6B
Miss −5.49%
Revenue · est. $4.9B
+37.3%
Beating market
OSCR vs S&P since report
2 quarters
Consecutive EPS beats

Market Reaction

% change · around the report
−8%−4%0+4%May 6May 7report 6:19am ETearnings+0.4%+2.4%
−8%−4%0+4%May 6May 7earnings+0.4%+2.4%
OSCR +2.4%S&P 500 +0.4%
−8%−4%0+4%May 6May 7report 6:19am ETearnings+0.6%+2.4%
−8%−4%0+4%May 6May 7earnings+0.6%+2.4%
OSCR +2.4%NASDAQ +0.6%
−9%0+9%+18%May 5May 14report 6:19am ETearnings+1.9%+19.5%
−9%0+9%+18%May 5May 14earnings+1.9%+19.5%
OSCR +19.5%S&P 500 +1.9%
−9%0+9%+18%May 5May 14report 6:19am ETearnings+3.4%+19.5%
−9%0+9%+18%May 5May 14earnings+3.4%+19.5%
OSCR +19.5%NASDAQ +3.4%
+10.59%
Day of report
+5.19%
Next session
+19.05%
One week
+38.05%
30 days

S&P 500 over the same 30 days: +0.73%.

Did OSCR Beat Earnings? Q1 2026 Results

Oscar Health delivered a blowout first quarter in 2026, posting earnings of $2.07 per diluted share on revenue of $4.65 billion, a 52.5% jump from the year-ago period, as surging membership and a dramatically improved medical loss ratio combined to more than double operating income to $704.09 million. The single biggest driver was a meaningful tightening of the medical loss ratio to 70.5% from 75.4% a year earlier, fueled by disciplined pricing, favorable claims seasonality, and $68.00 million of favorable prior-period reserve development that contrasted sharply with $31.00 million of unfavorable development in Q1 2025. Individual and Small Group membership reached 3.17 million as of March 31, up from roughly 2.02 million a year ago, providing substantial premium scale even as risk adjustment transfers grew alongside the membership base. Net income attributable to Oscar came in at $679.00 million, compared to $275.27 million in Q1 2025, and <a href="https://247wallst.com/investing/2026/03/07/oscar-healths-ceo-says-2026-is-the-year-it-finally-turns-a-profit-heres-what-hes-betting-on/">the company's profitability push</a> remains on course, with management reaffirming its full-year 2026 guidance and signaling confidence in significantly expanding margins throughout the year.

Key Takeaways
  • Higher membership driving revenue growth
  • Rate increases contributing to revenue growth
  • Medical loss ratio improvement to 70.5% from 75.4% due to disciplined pricing strategy
  • $68 million of favorable prior period reserve development vs $31 million unfavorable in Q1 2025
  • Claims and risk adjustment seasonality from metal and new member mix
  • Greater fixed cost leverage reducing SG&A expense ratio
  • Individual and Small Group membership grew to 3,174,489 from 2,021,484 year-over-year

“Oscar Health drove solid first-quarter performance with significant year-over-year improvements across our core metrics. We are reaffirming our guidance and remain on track to significantly expand margins and achieve meaningful profitability in 2026. Consumers expect to shop for healthcare like everyday products – on choice, price, and value. Oscar's exceptional technology, lifestyle products, and member experience deliver exactly that. The workforce is shifting, the individual market is resilient, and Oscar is leading the transition to a consumer-driven health economy.”

Oscar Health CEO, on the earnings call

Forward Guidance & Outlook

Oscar Health reaffirmed its full year 2026 outlook across all metrics, as originally provided in its February 10, 2026 financial results press release. The company stated it remains on track to significantly expand margins and achieve meaningful profitability in 2026.

OSCR YoY Financials

Q1 2026 vs Q1 2025 · SEC filings Q1 2025 Q1 2026
$0$2.0B$4.0B$3.0B$4.6BRevenue$288.2M$704.1MOperating Income$275.3M$679.0MNet Income
$0$2.0B$4.0BRevenueOperating IncomeNet Income

OSCR Revenue by Segment

Individual & Small Group

Figures from SEC filings and company reports. Not investment advice.